NeuroSense Therapeutics (NASDAQ:NRSN) CEO Alon Ben-Noon Buys 250,000 Shares

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) CEO Alon Ben-Noon acquired 250,000 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were bought at an average cost of $0.80 per share, for a total transaction of $200,000.00. Following the acquisition, the chief executive officer owned 4,534,233 shares of the company’s stock, valued at $3,627,386.40. This represents a 5.84% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

NeuroSense Therapeutics Stock Performance

NRSN stock traded up $0.01 during midday trading on Wednesday, reaching $0.71. 228,051 shares of the company were exchanged, compared to its average volume of 174,519. NeuroSense Therapeutics Ltd. has a 1-year low of $0.63 and a 1-year high of $2.52. The stock’s 50-day simple moving average is $0.78 and its 200 day simple moving average is $0.86. The company has a market cap of $22.95 million, a price-to-earnings ratio of -1.31 and a beta of 1.56.

Wall Street Analyst Weigh In

NRSN has been the topic of a number of research reports. D. Boral Capital restated a “buy” rating and set a $14.00 target price on shares of NeuroSense Therapeutics in a research report on Wednesday, April 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeuroSense Therapeutics in a report on Friday, May 8th. Finally, Roth Mkm initiated coverage on shares of NeuroSense Therapeutics in a report on Tuesday, March 10th. They issued a “buy” rating and a $3.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Institutional Trading of NeuroSense Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Two Sigma Investments LP purchased a new stake in shares of NeuroSense Therapeutics during the 3rd quarter worth $26,000. Jane Street Group LLC purchased a new stake in shares of NeuroSense Therapeutics during the 2nd quarter worth $54,000. Yorkville Advisors Global LP purchased a new stake in shares of NeuroSense Therapeutics during the 4th quarter worth $77,000. Finally, Squarepoint Ops LLC boosted its position in shares of NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after purchasing an additional 45,450 shares in the last quarter. Hedge funds and other institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.